[{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise aims to develop coronavirus vaccine and drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise introduces PolyTope mAb therapy to tackle coronavirus pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"State of North Dakota ","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoPrecise Awarded Grant Focused on Coronavirus and Other Emerging Pathogens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope\u2122 Monoclonal Antibody Cocktail Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data from ImmunoPrecise\u2019s Drug Pipeline to be Presented During the BIO International Partnering Event","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Histopathology Data from ImmunoPrecise's Polytope \u2122 Program Confirm Reduction in Lung Inflammation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise\u2019s Drug Pipeline to be Presented at BIO International Partnering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IPA Updates On Investigational New Drug (IND) Enabling Program for PolyTope\u00ae TATX-03","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IPA\u2019s Advanced PolyTope\u00ae TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histopathology Data of Preclinical Repeated Dose Toxicity Study and Ex Vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA\u2019s PolyTope\u00ae TATX-03, a Synergistic Antibody Cocktail against SARS\u2011CoV\u20112","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Ludwig-Maximilians-University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Live Virus Assays at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen Confirm PolyTope\u2019s Efficacy Against SARS-CoV-2 Variants Including BA.5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"OmniAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IPA\u2019s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Libera Bio","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoPrecise Antibodies\u2019 Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoPrecise\u2019s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Proposed Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Closing of $1.265 Million Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Pricing of $1.1 Million Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"}]
Find Clinical Drug Pipeline Developments & Deals by ImmunoPrecise
The Company intends to use the net proceeds from the proposed offering for research and development of its aproprietary LENS integrated intelligence technology for powerful antibody discovery.
The Company intends to use the net proceeds from the proposed offering for research and development of its aproprietary LENS integrated intelligence technology for powerful antibody discovery.
The net proceeds from the proposed offering for research and development, including its optimize proprietary LENS Integrated Intelligence Technology in silico generated antibodies.
The companies will jointly conduct research activities to identify and optimize proprietary LENS Integrated Intelligence Technology in silico generated antibodies, targeting an undisclosed target in the TME, as potential therapeutic development candidates.
Talem and Libera Bio will jointly develop novel antibodies for use with MPN delivery. The program will leverage BioStrand’s LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio’s Multifunctional Polymeric Nanocapsules (MPN Technology®).
Under the terms of the agreement, Talem will oversee the development and optimization of the antibodies for each program. OmniAb and Talem will share downstream economics upon potential out-licensing or commercialization of the OmniChicken-derived antibody.
The blinded studies examined the efficacy of IPA’s PolyTope® TATX-03 antibody combination therapy alongside in-house derived formulations of several commercially approved antibodies.
IND-enabling safety evaluations of PolyTope® TATX-03, executed under GLP standards and regulatory guidelines, revealed no in vivo adverse effects during histopathological examination nor any undesirable off-target binding to human biomaterials.
IPA's PolyTope® TATX-03 shows continuous validation of potent in vitro neutralizing activity against SARS-CoV-2 variants of concern, as further demonstrated against the Omicron sublineage BA.2.
In vivo, IND enabling evaluations of PolyTope® TATX-03, antibody cocktail therapy in the animal model showed that there were no pharmacokinetic aberrations and, injection with TATX-03 is well tolerated – with a significant safety margin and no clinical signs of toxicity.